Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11591034 | 0.87 | ALDH1A1 (0.67) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1704376 | 0.87 | ALDH1A1 (0.71) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5530832 | 0.86 | ALDH1A1 (0.58) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11879059 | 0.86 | ALDH1A1 (0.58) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11578632 | 0.86 | ALDH1A1 (0.55) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1532370 | 0.85 | MAPT (0.66) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10644315 | 0.84 | ALDH1A1 (0.57) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10889343 | 0.84 | ALDH1A1 (0.63) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9690338 | 0.83 | ALDH1A1 (0.78) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9690346 | 0.83 | ALDH1A1 (0.78) | KCNMA1ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KCNMA1 1655/4885ALDH1A1 2069/4885NPC1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.